cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cogent Biosciences Inc
6 own
3 watching
Current Price
$9.98
$-0.04
(-0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
902.27M
52-Week High
52-Week High
15.68000
52-Week Low
52-Week Low
9.61000
Average Volume
Average Volume
1.54M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-6.94029851
iconMarket Capitalization902.27M
icon52-Week High15.68000
icon52-Week Low9.61000
iconAverage Volume1.54M
iconDividend Yield--
iconP/E Ratio-6.94029851
What does the Cogent Biosciences Inc do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cogent Biosciences Inc make?
News & Events about Cogent Biosciences Inc.
Stock Options Channel
2 months ago
Investors eyeing a purchase of Cogent Biosciences Inc (COGT) stock, but cautious about paying the going market price of 11.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2025 ...
TipRanks Financial Blog
5 months ago
Needham analyst Ami Fadia maintained a Buy rating on Cogent Biosciences (COGT Research Report) yesterday and set a price target of $23.00. The co... Needham analyst Ami Fadia maintained a Buy rating on Cogent Biosciences (COGT Research R...
Globe Newswire
5 months ago
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a novel, selective, reversible FGFR2 inhibitor has potency against molecular brake mutations and potential advantages over covalent approaches ...
Globe Newswire
5 months ago
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences: ...
Globe Newswire
7 months ago
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will ...
Frequently Asked Questions
Frequently Asked Questions
What is Cogent Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Cogent Biosciences Inc shares?
plus_minus_icon
How can I buy Cogent Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Cogent Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cogent Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Cogent Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Cogent Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cogent Biosciences Inc?
plus_minus_icon
What percentage is Cogent Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cogent Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.98
$-0.04
(-0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
INHIBRX INC
INHIBRX INC
$19.23
$-0.25 (-1.28 %)
Avid Bioservices Inc
Avid Bioservices Inc
$9.69
$0.09 (0.94 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$16.35
$-0.29 (-1.74 %)
Cassava Sciences Inc
Cassava Sciences Inc
$17.82
$0.28 (1.60 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
INHIBRX INC
INHIBRX INC
$19.23
$-0.25 (-1.28 %)
Avid Bioservices Inc
Avid Bioservices Inc
$9.69
$0.09 (0.94 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$16.35
$-0.29 (-1.74 %)
Cassava Sciences Inc
Cassava Sciences Inc
$17.82
$0.28 (1.60 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00